KILIÇ, L. Et Al. 2017. Tocilizumab Had Acceptable Retention Rate in Both Randomized Controlled Trials and Observational Studies: Systematic Review of Rheumatoid Arthritis. ACR/ARHP 2017 , (SAN DİEGO, United States Of America).

KILIÇ, L., KÜÇÜKŞAHİN, O., ÖZBALKAN, Z., BES, C., YAZISIZ, V., YAZICI, A., ... SOLMAZ, D.(2017). Tocilizumab Had Acceptable Retention Rate in Both Randomized Controlled Trials and Observational Studies: Systematic Review of Rheumatoid Arthritis . ACR/ARHP 2017, SAN DİEGO, United States Of America

KILIÇ, LEVENT Et Al. "Tocilizumab Had Acceptable Retention Rate in Both Randomized Controlled Trials and Observational Studies: Systematic Review of Rheumatoid Arthritis," ACR/ARHP 2017, SAN DİEGO, United States Of America, 2017

KILIÇ, LEVENT Et Al. "Tocilizumab Had Acceptable Retention Rate in Both Randomized Controlled Trials and Observational Studies: Systematic Review of Rheumatoid Arthritis." ACR/ARHP 2017 , SAN DİEGO, United States Of America, 2017

KILIÇ, L. Et Al. (2017) . "Tocilizumab Had Acceptable Retention Rate in Both Randomized Controlled Trials and Observational Studies: Systematic Review of Rheumatoid Arthritis." ACR/ARHP 2017 , SAN DİEGO, United States Of America.

@conferencepaper{conferencepaper, author={LEVENT KILIÇ Et Al. }, title={Tocilizumab Had Acceptable Retention Rate in Both Randomized Controlled Trials and Observational Studies: Systematic Review of Rheumatoid Arthritis}, congress name={ACR/ARHP 2017}, city={SAN DİEGO}, country={United States Of America}, year={2017}}